strong result rais guidanc support on-going share
tender rais sale ep estim year product drive
standout growth albeit follow ep declin survey
dermatologist suggest remain well posit psoriasi could
player atop dermat
result increas ep estim vs consensu
guidanc rais ep estim
vs consensu vs consensu
anticip biosimilar competit prompt ep
declin ep compound-annual-growth-rate forecast unchang vs industri
averag support ep outlook tender offer common
stock price conclud end may model purpos
assum buy back share averag price
rais sale estim vs guidanc approach
sale compound-annual-growth-rate forecast unchang consist industri averag
trim oper margin estim vs guidanc
margin target intact
thereaft forecast rais oper margin forecast
increas vs last-publish expect
provid guidanc mani item forecast
guidanc guidanc look humira sale vs estimate total
sale vs estimate oper margin vs estimate double-
digit ep growth vs estimate suggest opportun upward
revis time
survey dermatologist see psoriasi aotc report suggest
remain well posit psoriasi could player atop dermat humira
like lose share psoriasi class risankizumab promis
candid expect lead year biosimilar tnf expect acceler
eros kol forecast uptak gradual/slow atop dermat
upadacitinib jak inhibitor view modestly/meaning better sni dupix
jak inhibitor class expect split atop dermat market dupix
pleas see page report import disclosur
provid long-term guidanc expect humira appear
solid foot forese futur competit posit
hepat segment oncolog compani pipelin promis
agent opportun upward revis sever front stock
attract valu versu group overal attribut argu purchas
mavyret nex-gen hcv rollout
elagolix approv endometriosi
humira sale
biosimilar competit
humira biosimilar gain traction
quickli eu and/or launch
especi oncolog
global biopharmaceut compani product use treat rheumatoid
chronic kidney diseas among other humira ra crohn domin
product repres total sale profit also pipelin
compound indic phase ii phase develop
compani data cowen compani
compani data cowen compani
ww foreign lc ex foreign sale report portion foreign leuprolid foreign lc ex leuprolid foreign lc ex cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
compani data cowen compani
ww ip expect hold till post settlement samsung launch humira biosimilar anticip enbrel foreign lc ex ra pa crohn psoriasi jai uc uveiti hshumira adalimumab anti-tnf mab guidanc approach guidanc peak record sale foreign sale report includ sale total portion foreign record share ou profitsimbruvica approv hematolog cancer pcyc acq close acquir solvay pacrealipas enzym replac pancreat insufficiencysynthroid steadi sale gener difficult formul synthroid levothyroxin overact thyroidlupron leuprolid line extens support foreign lc ex leuprolid gener avail lupron still lead market mo depotsynagi guidelin chang could pressur use adopt ou foreign lc ex human mab bind f-protein rsvdepakot divalproex acid seizur control bipolar mania ir patent expir er patent expir cowen
compani data cowen compani
 patent expir maintain share via servic foreign lc ex induct mainten gener anesthesiaultane/sevofluoran flourin isopropyl ether anesthesiaandrogel gener form launch franchiseandrogel testosteron gel hypergonad market declinekaletra lopinavir/low-dos ritonavir combo hiv patent exp market em aluvia combo proteas inhibitor foreign lc ex emerg market slow sale declinenorvir patent expir januari inhibit cytochrom metabol pi foreign lc ex ritonavir hiv proteas inhibitor use booster combozemplar teva gener launch foreign lc ex paricalcitol tx secondari hyperparathyroid pt ckftricor/trilipix gener launch gener launch via settlement teva/brl foreign lc ex er niacin rais hdl reduc ldlother includ gross-to-net adjust assum ceas humira patent us includ nimbex vicodin etc emerg mkt growth foreign lc ex modest growth project cowen
compani data cowen compani
 combin glecaprevir pi pibrentasvir inhibitor hcv dose tablet qd week eign lc ex all-or regimen genotyp ifn-nav hcv patientsmavyret patient without cirrhosi new treatmentviekirax exviera combin paritaprebir/r pi ombitasvir inhibitor dasabuvir non-nuc polymeras inhibitor hcv eign lc ex all-or regimen genotyp ifn-nav hcv patientsviekirax exviera ww guidanc profit roch incom line royalti estimate sale roch condit eu approv eign lc ex delet indic approv standard refractori file venetoclax select inhibitor cllelagolix- oral gnrh antagonist partial estrogen suppress endometriosi file ph uterin fibroid partnership neurocrin eign lc ex similar lupron zoladexelagolix hold ww right elagolix gnrh antagonistsrova-t meru sclc mainten complet taho complet eign lc ex stem cell technolog solid tumor target peak salesrova-t stemcentrx acq conting payment close guidanc phase psoriasi phase ii crohn pa eign lc ex month bi bi receiv mileston royaltiesduodopa infus directli small intestin via portabl pump like nich product refractori pd eign lc ex market solvay ousduodopa gel formul carbidopa/levodopa parkinson supadacitinib guidanc file base studi atop dermat data eign lc ex jak inhibitor competit profil ra crohn uc ad cowen
compani data cowen compani
 partner record profit record royalti ex-u foreign lc ex elotuzumab antibodi multipl foreign lc ex trial fail glioblastoma filingveliparib bid oral dose cross bbb foreign lc ex parp inhibitor ovarian cancer phase zinbryta foreign lc ex fx zinbryta daclizumab withdrawn global march foreign lc ex foreign lc ex guidanc annual revenu growth cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ heavi depend humira sale ep success pipelin
product notabl hepat portfolio success independ compani
